Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#3869 Sunitinib for the treatment of advanced pheochromocytomas/paragangliomas – A phase 2 clinical trial

Introduction: Malignant pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors with limited treatment options. Here, we report the preliminary results of SUTNET trial assessing safety and efficacy of sunitinib in advanced/unresectable PPGLs.

Conference:

Presenting Author: Prinzi N

Authors: Prinzi N, Corti F, Capone I, Perrone F, Tamborini E,

Keywords: pheochromocytoma, paraganglioma, sunitinib, neuroendocrine,

#3733 New insights on the clinical role of Ki-67 and spindle cell and oncocytic histological variants in lung carcinoid tumors

Introduction: WHO classification defines lung carcinoid tumors (LCTs) as well-differentiated neuroendocrine neoplasms classified in typical (TC) and atypical carcinoids (AC). Morphologic factors and protein expression able to predict recurrence after surgical curative resection are little known. Ki-67 and spindle cell and oncocytic histological variants may impact on differential diagnosis, but their clinical relevance is much debated.

Conference:

Presenting Author: Milione M

Authors: Centonze G, Maisonneuve P, Grillo F, Prinzi N, Lagano V,

Keywords: lung carcinoid, Ki-67, spindle cell, oncocytic, Immunohistochemistry,

#3671 GEP-NET and early progression after RLT – Application of a modified TGR to increase the accuracy of prediction

Introduction: Tumor Growth Rate (TGR) allows for early SSA and RLT response assessment in NET.

Conference:

Presenting Author: Scalorbi F

Authors: Scalorbi F, Calareso G, Garanzini E, Prinzi N, Pusceddu S,

Keywords: TGR, RLT, NET,

#3543 Safety of Lanreotide Autogel (LAN) 120 mg plus Metformin (MET) in patients with advanced, well-differentiated (WD) gastro-intestinal (GI) or lung neuroendocrine tumors (NETs) - A pilot, open-label, prospective study: The MetNET-2 Trial (NCT02823691)

Introduction: Preclinical and clinical evidence supports a potential role for MET as an antineoplastic agent in WD NETs.